MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Oncogene

• Publication date

  2004-01-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.onc.1207151PMID 14737110
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells

  2012cited by this paper
• MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model.

  2003cited by this paper
• The p53 pathway and its inactivation in neuroblastoma.

  2003cited by this paper
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: A potential role in neuroblastoma therapy

  2002cited by this paper
• Identification of DNA-protein interactions in the 5' flanking and 5' untranslated regions of the human multidrug resistance protein (MRP1) gene: evaluation of a putative antioxidant response element/AP-1 binding site.

  2001cited by this paper
• p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells.

  2001cited by this paper
• N‐myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis

  2001cited by this paper
• MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells

  2001cited by this paper
• Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells.

  2000cited by this paper
• Expression analysis of multidrug resistance associated genes in neuroblastomas.

  1999cited by this paper
• Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells

  1999influential reference
• Expression of MRP and cMOAT in Childhood Neuroblastomas and Malignant Liver Tumors and Its Relevance to Clinical Behavior

  1998influential reference
• Sequential expression of the MAD family of transcriptional repressors during differentiation and development

  1998cited by this paper
• Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer.

  1998cited by this paper
• The interferon-inducible murine p48 (ISGF3gamma) gene is regulated by protooncogene c-myc.

  1997cited by this paper
• The prognostic value of MDR1 gene expression in primary untreated neuroblastoma.

  1997cited by this paper
• Myc target genes.

  1997cited by this paper
• Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma.

  1997cited by this paper
• Targeted expression of MYCN causes neuroblastoma in transgenic mice

  1997cited by this paper
• Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells.

  1996cited by this paper
• Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma.

  1996influential reference
• Evidence that SP1 Modulates Transcriptional Activity of the Multidrug Resistance-Associated Protein Gene

  1996cited by this paper
• Altered growth and phenotype in clonal mycN transfectants of the sk‐n‐sh neuroblastoma cell line

  1994cited by this paper
• Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.

  1992cited by this paper
• P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma.

  1991cited by this paper
• Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line.

  1991cited by this paper
• Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies.

  1991cited by this paper
• Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.

  1991cited by this paper
• Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity.

  1990cited by this paper
• Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas.

  1990cited by this paper
• Preparation of extracts from higher eukaryotes.

  1990cited by this paper
• Sequence-specific DNA binding by the c-Myc protein.

  1990cited by this paper
• Expression of the multidrug resistance, MDR1, gene in neuroblastomas.

  1990cited by this paper
• Principles and Practice of Pediatric Oncology

  1989cited by this paper
• Resistance to drugs associated with the multidrug resistance phenotype following selection with high-concentration methotrexate.

  1989cited by this paper
• Construction of plasmids that express E. coli beta-galactosidase in mammalian cells.

  1989cited by this paper
• Identification and characterization of the NMYC gene product in human neuroblastoma cells by monoclonal antibodies with defined specificities.

  1986cited by this paper
• Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.

  1985cited by this paper
• Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

  1984cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper

• Phase separation-based screening identifies arsenic trioxide as the N-Myc-DNA interaction inhibitor for neuroblastoma therapy.

  2025cites this paper
• Characterization of a deazaflavin analog as a potent inhibitor of multidrug resistance-associated protein 1.

  2024cites this paper
• Advances and challenges in therapeutic resistant biomarkers of neuroblastoma: A comprehensive review.

  2024cites this paper
• ABCC1 Is a ΔNp63 Target Gene Overexpressed in Squamous Cell Carcinoma

  2024cites this paper
• Extracellular Vesicles and Cancer Multidrug Resistance: Undesirable Intercellular Messengers?

  2023cites this paper
• CCNB1IP1 prevents ubiquitination‐mediated destabilization of MYCN and potentiates tumourigenesis of MYCN‐amplificated neuroblastoma

  2023cites this paper
• Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?

  2023cites this paper
• P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease

  2022cites this paper
• Recent advances in the developmental origin of neuroblastoma: an overview

  2022cites this paper
• MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma

  2022cites this paper
• Genetics of Pediatric Tumors

  2021cites this paper
• Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition.

  2021cites this paper
• A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma

  2021cites this paper
• Excellent Early Outcomes of Combined Chemotherapy With Arsenic Trioxide for Stage 4/M Neuroblastoma in Children: A Multicenter Nonrandomized Controlled Trial

  2021cites this paper
• The Combination of the M2 Muscarinic Receptor Agonist and Chemotherapy Affects Drug Resistance in Neuroblastoma Cells

  2020cites this paper
• Nobiletin in Cancer Therapy: How This Plant Derived-Natural Compound Targets Various Oncogene and Onco-Suppressor Pathways

  2020cites this paper
• Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC–Driven Cancer Progression

  2020cites this paper
• Pharmacodynamic mechanisms of anti-inflammatory drugs on the chemosensitization of multidrug-resistant cancers and the pharmacogenetics effectiveness

  2020cites this paper
• Pharmacodynamic mechanisms of anti-inflammatory drugs on the chemosensitization of multidrug-resistant cancers and the pharmacogenetics effectiveness

  2020cites this paper
• Role of Genetic and Epigenetic Alterations in Pathogenesis of Neuroblastoma

  2019cites this paper
• MYCN-mediated regulation of the HES1 promoter enhances the chemoresistance of small-cell lung cancer by modulating apoptosis.

  2019cites this paper
• Nobiletin Enhances Chemosensitivity to Adriamycin through Modulation of the Akt/GSK3β/β–Catenin/MYCN/MRP1 Signaling Pathway in A549 Human Non-Small-Cell Lung Cancer Cells

  2018cites this paper
• UBE4B LEVELS DETERMINE THE EFFICACY OF EGFR AND STAT5 INHIBITORS IN TREATMENT RESISTANT NEUROBLASTOMA

  2018cites this paper
• Molecular Biology of ABC Transporters

  2018cites this paper
• GD2‐targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma

  2018cites this paper
• MiRNA-124-3p Reduces Cell Viability in Cisplatin Resistant Neuroblastoma Cell Models.

  2017influential citation
• Nanoparticle delivery of curcumin induces cellular hypoxia and ROS-mediated apoptosis via modulation of Bcl-2/Bax in human neuroblastoma.

  2017cites this paper
• Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors

  2016cites this paper
• Drug Transporters and Multiple Drug Resistance in Pediatric Solid Tumors.

  2016cites this paper
• Suppression of c-Myc is involved in multi-walled carbon nanotubes' down-regulation of ATP-binding cassette transporters in human colon adenocarcinoma cells.

  2015cites this paper
• MRP1 and its role in anticancer drug resistance

  2015cites this paper
• ABC transporters and neuroblastoma.

  2015cites this paper
• MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma

  2015cites this paper
• Modulation of chemotherapeutic drug resistance in neuroblastoma SK‐N‐AS cells by the neural apoptosis inhibitory protein and miR‐520f

  2015cites this paper
• Putative stem cell markers in cervical squamous cell carcinoma are correlated with poor clinical outcome

  2015cites this paper
• miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells

  2014cites this paper
• Thrombin conducts epithelial‑mesenchymal transition via protease‑activated receptor‑1 in human gastric cancer.

  2014cites this paper
• Importance of ABCC1 for cancer therapy and prognosis

  2014cites this paper
• Targeting MYCN in Pediatric Solid Tumors

  2014cites this paper
• Pharmacogenomic characterization of gemcitabine response – a framework for data integration to enable personalized medicine

  2013cites this paper
• Multidrug Resistance and Cancer Stem Cells in Neuroblastoma and Hepatoblastoma

  2013cites this paper
• The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis

  2013cites this paper
• Apoptotic Cell Death in Neuroblastoma

  2013cites this paper
• The MYCN Oncogene

  2013cites this paper
• Studies of the misprocessing mutations R1202D and E1204K in the drug and organic anion transporter, MRP1 (ABCC1) in cultured HEK cells

  2013cites this paper
• MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome

  2012cites this paper
• MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome

  2012cites this paper
• Clusterin (CLU) and its interacting proteins in cell signalling and neuroblastoma

  2012cites this paper
• MYCN, neuroblastoma and focal adhesion kinase (FAK).

  2011cites this paper
• Chalcogenopyrylium Dyes as Modulators of Multidrug Resistance Protein (MRP) 1

  2011cites this paper
• ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux

  2011cites this paper
• Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells

  2011cites this paper
• Direct and Coordinate Regulation of ATP-binding Cassette Transporter Genes by Myc Factors Generates Specific Transcription Signatures That Significantly Affect the Chemoresistance Phenotype of Cancer Cells*

  2010cites this paper
• Regulation of hepatic ABCC transporters by xenobiotics and in disease states

  2010cites this paper
• Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up‐regulating glutamate cysteine ligase

  2010cites this paper
• MYCN oncoprotein targets and their therapeutic potential.

  2010cites this paper
• Myc proteins as therapeutic targets

  2010cites this paper
• Focal Adhesion Kinase with the Interacting Proteins and Signaling in Cancer

  2010cites this paper
• Redox Regulation of Multidrug Resistance in Cancer Chemotherapy: Molecular Mechanisms and Therapeutic Opportunities

  2009cites this paper
• MycN is a transcriptional regulator of livin in neuroblastoma.

  2009cites this paper
• High level MycN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity.

  2009cites this paper
• Tubedown in neuroblastic tumors

  2009cites this paper
• Pharmacogenomics Approach Reveals MRP1 (ABCC1)-Mediated Resistance to Geldanamycins

  2009cites this paper
• Expression of MRP1 gene in acute leukemia

  2008cites this paper
• Math 1 target genes are enriched with evolutionarily conserved clustered e-box binding sites

  2007cites this paper
• Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells.

  2007cites this paper
• Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification.

  2007cites this paper
• Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma.

  2007cites this paper
• 1H MRS identifies specific metabolite profiles associated with MYCN‐amplified and non‐amplified tumour subtypes of neuroblastoma cell lines

  2007cites this paper
• N-MYC Regulates Focal Adhesion Kinase Expression in Human Neuroblastoma*

  2007cites this paper
• Expression of MYCN in pediatric synovial sarcoma

  2007cites this paper
• Role of the MRP1/ABCC1 Multidrug Transporter Protein in Cancer

  2007cites this paper
• TRANSCRIPTION REGULATION OF ABC DRUG TRANSPORTERS BY MYC ONCOPROTEINS

  2007cites this paper
• The Role of Multi-Drug Resistance Associated Protein 4 and P-glycoprotein in Resistance of Neuroblastoma to Topotecan and Irinotecan

  2007cites this paper
• Molecularly guided therapy of neuroblastoma: a review of different approaches.

  2006cites this paper
• Molecular cytogenetic characterization of doxorubicin‐resistant neuroblastoma cell lines: Evidence that acquired multidrug resistance results from a unique large amplification of the 7q21 region

  2006cites this paper
• Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.

  2006cites this paper
• Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters

  2006cites this paper
• Sphingolipids, ABC transporters and chemosensitivity in neuroblastoma

  2006cites this paper
• Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.

  2006cites this paper
• Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.

  2006cites this paper
• Treatment of Relapsed and Refractory Neuroblastoma

  2005cites this paper
• The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome.

  2005cites this paper
• Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro

  2005cites this paper
• Sensitivity to Gemcitabine and Its Metabolizing Enzymes in Neuroblastoma

  2005cites this paper
• High mobility group A1 is a molecular target for MYCN in human neuroblastoma.

  2005cites this paper
• MYCN amplification remains prognostically strong 20 years after its "clinical debut".

  2004cites this paper